Therapies

With the introduction of this glucagon-like peptide-1 receptor agonist (GLP-1 RA), efpeglenatide, could we see new cardiovascular and renal benefits for patients with type 2 diabetes?

How does basal insulin compare to other diabetes medications in its impact on cholesterol and triglycerides?

Male, 72 years of age, type 2, insulin-requiring diabetes, also taking SGLT-2. Annual physical. No urinary complaints during the visit. Received annual lab work end of the workday, glucose elevated much higher than the reports. WBC elevated, 1200, no urine culture, but U/A did show cloudy....

American Diabetes Association symposium presents new phase 3 clinical trials of SURPASS-3 and SURPASS-5. 

Researchers assess the safety of intranasal insulin as a treatment for type 2 diabetes-associated cognitive impairment in aging adult populations. 

The internet has many different opinions of what an optimal diet is for athletes, but what do the experts say?
With exclusive commentary from Sheri Colberg, PhD.

Dapagliflozin has shown clinical effectiveness in some of the same metabolic processes that are affected by COVID-19, but can it help treat patients who have contracted the virus?

Real-world data for the Medtronic Extended-Wear Infusion Set revealed at the 81st American Diabetes Association scientific session.

American Diabetes Association mini-symposium presented by Biykem Bozkurt, MD, Ph.D., FHFSA, FACC, FAHA, FESC. 

The GRADE Study is the most comprehensive study comparing multiple diabetic medications to assess efficacy in type 2 diabetes. So which drug therapy reigned supreme?